By Sabela Ojea


Shares of MoonLake Immunotherapeutics climbed after the company said it received positive 24-week results from a trial to treat patients with a chronic inflammatory skin condition.

The stock was up 13% Monday at $61.83.

The clinical-stage biopharmaceutical company said its phase 2 Mira trial showed that maintenance treatment with its sonelokimab treatment led to further improvements in patients with moderate-to-severe hidradenitis suppurativa.

MoonLake Chief Executive Jorge Santos da Silva said the company is on track to discuss its phase 3 development plans with the Food and Drug Administration by the end of the year.


Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix


(END) Dow Jones Newswires

10-16-23 1220ET